ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression

Oncogene

Volumn 25, Issue 39, 2006, Pages 5462-5466

  Peduto, L ^a   Reuter, V E ^a   Sehara Fujisawa, A ^b   Shaffer, D R ^a   Scher, H I ^a   Blobel, C P ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ADAM12; Metalloprotease disintegrin; Prostate cancer; Stromal tumor cell interaction

Indexed keywords

A DISINTEGRIN AND METALLOPROTEASE 12; ALPHA SMOOTH MUSCLE ACTIN; MEMBRANE PROTEIN; METALLOPROTEINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CELL INTERACTION; CELL SUBPOPULATION; COLON CARCINOMA; EPITHELIUM TUMOR; HUMAN; INTESTINE CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE TUMOR; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STROMA CELL; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ADAM PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INTESTINAL NEOPLASMS; MALE; MAMMARY NEOPLASMS, ANIMAL; MICE; PROSTATIC NEOPLASMS; STROMAL CELLS;

EID: 33748331284     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209536     Document Type: Article

References (22)

1. Adam RM, Kim J, Lin J, Orsola A, Zhuang L, Rice DC et al. (2002). Endocrinology 143: 4599-4608.
2. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T et al. (2002). Nat Med 8: 35-40.
3. Bhowmick NA, Neilson EG, Moses HL. (2004). Nature 432: 332-337.
4. Blobel CP. (2005). Nat Rev Mol Cell Biol 6: 32-43.
5. Cunha GR, Hayward SW, Wang YZ, Ricke WA. (2003). Int J Cancer 107: 1-10.
6. Desmouliere A, Guyot C, Gabbiani G. (2004). Int J Dev Biol 48: 509-517.
7. Freeman MR, Paul S, Kaefer M, Ishikawa M, Adam RM, Renshaw AA et al. (1998). J Cell Biochem 68: 328-338.
8. Guy CT, Cardiff RD, Muller WJ. (1992). Mol Cell Biol 12: 954-961.
9. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM. (1999). Am J Pathol 154: 1489-1501.
10. Kodama T, Ikeda E, Okada A, Ohtsuka T, Shimoda M, Shiomi T et al. (2004). Am J Pathol 165: 1743-1753.
11. Kurisaki T, Masuda A, Osumi N, Nabeshima Y, Fujisawa-Sehara A. (1998). Mech Dev 73: 211-215.
12. Kveiborg M, Frohlich C, Albrechtsen R, Tischler V, Dietrich N, Holck P et al. (2005). Cancer Res 65: 4754-4761.
13. Le Pabic H, Bonnier D, Wewer UM, Coutand A, Musso O, Baffet G et al. (2003). Hepatology 37: 1056-1066.
14. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM. (2000). Biochem Biophys Res Commun 278: 511-515.
15. Lu Z, Ghosh S, Wang Z, Hunter T. (2003). Cancer Cell 4: 499-515.
16. Manova K, Bachvarova RF, Huang EJ, Sanchez S, Pronovost SM, Velazquez E et al. (1992). J Neurosci 12: 4663-4676.
17. Moser AR, Pitot HC, Dove WF. (1990). Science 247: 322-324.
18. Peduto L, Reuter VE, Shaffer DR, Scher HI, Blobel CP. (2005). Cancer Res 65: 9312-9319.
19. Schuurmans AL, Bolt J, Mulder E. (1988). Mol Cell Endocrinol 60: 101-104.
20. Shaffer DR, Viale A, Ishiwata R, Leversha M, Olgac S, Manova K et al. (2005). Proc Natl Acad Sci USA 102: 210-215.
21. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA et al. (2004). Cancer Res 64: 2270-2305.
22. Torring N, Moller-Ernst Jensen K, Lund L, Nielsen JE, Djurhuus JC, Poulsen SS et al. (2002). BJU Int 89: 583-590.